MX2018002520A - Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. - Google Patents
Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.Info
- Publication number
- MX2018002520A MX2018002520A MX2018002520A MX2018002520A MX2018002520A MX 2018002520 A MX2018002520 A MX 2018002520A MX 2018002520 A MX2018002520 A MX 2018002520A MX 2018002520 A MX2018002520 A MX 2018002520A MX 2018002520 A MX2018002520 A MX 2018002520A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- salt
- novedous
- pirazolo
- pyrimidine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Proporcionar un compuesto novedoso que tiene un efecto inhibidor de HER2 y que tiene un efecto citostático; también se pretende proveer un medicamento útil en la prevención y/o tratamiento de una enfermedad que involucra HER2, particularmente, cáncer, con base en el efecto inhibidor de HER2; la presente invención proporciona un compuesto de la fórmula (I) en donde X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2 y R3 tienen significados como se definen en la presente especificación, o una sal del mismo.(ver formula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015172354 | 2015-09-01 | ||
| PCT/JP2016/075380 WO2017038838A1 (ja) | 2015-09-01 | 2016-08-31 | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002520A true MX2018002520A (es) | 2019-02-07 |
| MX373865B MX373865B (es) | 2020-03-26 |
Family
ID=58188946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002520A MX373865B (es) | 2015-09-01 | 2016-08-31 | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9920060B2 (es) |
| EP (1) | EP3345907B1 (es) |
| JP (1) | JP6141568B1 (es) |
| KR (1) | KR102075886B1 (es) |
| CN (1) | CN108349981B (es) |
| AU (1) | AU2016317521B2 (es) |
| BR (1) | BR112018004175B8 (es) |
| CA (1) | CA2997051C (es) |
| DK (1) | DK3345907T3 (es) |
| ES (1) | ES2799520T3 (es) |
| MX (1) | MX373865B (es) |
| MY (1) | MY191938A (es) |
| PH (1) | PH12018500437B1 (es) |
| PL (1) | PL3345907T3 (es) |
| PT (1) | PT3345907T (es) |
| RU (1) | RU2705579C2 (es) |
| SG (1) | SG11201801365YA (es) |
| TW (1) | TWI659957B (es) |
| WO (1) | WO2017038838A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3092254A4 (en) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating her2 positive tumors |
| MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| DK3269370T3 (da) | 2016-02-23 | 2020-04-06 | Taiho Pharmaceutical Co Ltd | Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf |
| EP3590516B1 (en) * | 2017-02-28 | 2025-09-03 | Taiho Pharmaceutical Co., Ltd. | Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CN106967303A (zh) * | 2017-05-02 | 2017-07-21 | 杭州福莱蒽特精细化工有限公司 | 一种艳色兰偶氮染料及其制备方法和应用 |
| AU2018322286B2 (en) | 2017-08-21 | 2022-03-10 | Taiho Pharmaceutical Co., Ltd. | Fusion protein of DCTN1 protein with RET protein |
| EP3845537B1 (en) * | 2018-08-29 | 2025-07-30 | Taiho Pharmaceutical Co., Ltd. | Crystal of pyrazolo[3,4-d]pyrimidine |
| TWI769395B (zh) * | 2018-08-29 | 2022-07-01 | 日商大鵬藥品工業股份有限公司 | 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑 |
| PT3909584T (pt) * | 2019-01-11 | 2024-01-12 | Taiho Pharmaceutical Co Ltd | Composto de pirimidina ou um seu sal |
| CN113336760B (zh) * | 2020-02-18 | 2022-11-04 | 深圳市塔吉瑞生物医药有限公司 | 取代的酰胺衍生物及其组合物及用途 |
| CN111440138A (zh) * | 2020-04-30 | 2020-07-24 | 中国林业科学研究院林产化学工业研究所 | 具有hdac抑制和抗肿瘤活性的新型漆酚基异羟肟酸衍生物的合成方法 |
| EP4183788A4 (en) | 2020-07-15 | 2024-07-17 | Taiho Pharmaceutical Co., Ltd. | PYRIMIDINE COMPOUND CRYSTAL |
| WO2022014639A1 (ja) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Ｅｇｆｒ阻害剤 |
| KR20230031926A (ko) | 2020-07-15 | 2023-03-07 | 다이호야쿠힌고교 가부시키가이샤 | 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합 |
| MX2023003362A (es) | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| AU2021357081A1 (en) * | 2020-10-05 | 2023-06-01 | Dana-Farber Cancer Institute, Inc | Potent and selective inhibitors of her2 |
| EP4225445A2 (en) | 2020-10-09 | 2023-08-16 | Scorpion Therapeutics, Inc. | Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| US20250161306A1 (en) * | 2022-01-25 | 2025-05-22 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CN114736207B (zh) * | 2022-04-28 | 2023-03-31 | 武汉九州钰民医药科技有限公司 | 一种小分子her2抑制剂的制备工艺 |
| WO2024254266A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641455B1 (en) * | 2003-06-27 | 2008-08-06 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| EP1968979A2 (en) | 2005-12-08 | 2008-09-17 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| KR102027598B1 (ko) * | 2011-05-17 | 2019-10-01 | 프린시피아 바이오파마, 인코퍼레이티드 | 타이로신 키나아제 저해제 |
| CA2841080A1 (en) * | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2657233B1 (en) | 2012-01-19 | 2014-08-27 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| MX360498B (es) | 2013-08-12 | 2018-11-05 | Taiho Pharmaceutical Co Ltd | Compuesto novedoso de pirimidina fusionada o sal del mismo. |
| CA2920534A1 (en) * | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
-
2016
- 2016-08-31 JP JP2017513832A patent/JP6141568B1/ja active Active
- 2016-08-31 MY MYPI2018700648A patent/MY191938A/en unknown
- 2016-08-31 PL PL16841868T patent/PL3345907T3/pl unknown
- 2016-08-31 EP EP16841868.9A patent/EP3345907B1/en active Active
- 2016-08-31 ES ES16841868T patent/ES2799520T3/es active Active
- 2016-08-31 AU AU2016317521A patent/AU2016317521B2/en active Active
- 2016-08-31 SG SG11201801365YA patent/SG11201801365YA/en unknown
- 2016-08-31 MX MX2018002520A patent/MX373865B/es active IP Right Grant
- 2016-08-31 BR BR112018004175A patent/BR112018004175B8/pt active IP Right Grant
- 2016-08-31 DK DK16841868.9T patent/DK3345907T3/da active
- 2016-08-31 TW TW105127978A patent/TWI659957B/zh active
- 2016-08-31 CA CA2997051A patent/CA2997051C/en active Active
- 2016-08-31 CN CN201680063691.7A patent/CN108349981B/zh active Active
- 2016-08-31 PT PT168418689T patent/PT3345907T/pt unknown
- 2016-08-31 KR KR1020187009035A patent/KR102075886B1/ko active Active
- 2016-08-31 WO PCT/JP2016/075380 patent/WO2017038838A1/ja not_active Ceased
- 2016-08-31 RU RU2018111439A patent/RU2705579C2/ru active
-
2017
- 2017-04-20 US US15/492,442 patent/US9920060B2/en active Active
-
2018
- 2018-02-28 PH PH12018500437A patent/PH12018500437B1/en unknown
- 2018-03-16 US US15/922,980 patent/US10329300B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002520A (es) | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| MX391981B (es) | Derivados de benzooxazol como inmunomoduladores. | |
| MX392026B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| PH12017502363A1 (en) | Brk inhibitory compound | |
| MX389513B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| DOP2015000216A (es) | Inhibidores de bromodominios tetraciclicos | |
| EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| GT201600123A (es) | Inhibidores de syk | |
| NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX390051B (es) | Antagonistas de ep4. | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| CR20170426A (es) | Inhibidores de bace 1 | |
| MX2020002812A (es) | Abx196 para usarse en el tratamiento del cancer de vejiga. | |
| MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| TH171407A (th) | สารประกอบไพริมิดีนที่ถูกเชื่อมหลอมใหม่หรือเกลือของสิ่งดังกล่าว |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |